Table 3.

MetaXL quality assessment score

Study	1. Population and observation period	2. Diagnostic criteria	3. Methods of case ascertainment	4. Administration of measurement protocol	5. Catchment area	6. Prevalence measure	Total (max: 11)
Aguilera et al. [18] (2007)	1	1	2	3	2	2	11
Bienvenu et al. [13] (2006)	1	1	2	1	2	2	9
Isaksen et al. [22] (2012)	1	1	2	3	2	2	11
Chakrabarti et al. [20] (2005)	1	1	2	2	2	1	9
Fombonne et al. [19] (2003)	1	1	1	3	2	2	10
Magnússon et al. [14] (2001)	1	1	1	1	2	2	8
Strømme et al. [15] (2000)	1	1	2	3	2	2	11
Sarajlija et al. [17] (2015)	1	1	1	2	2	2	9
Fehr et al. [21] (2011)	1	1	2	2	2	2	10
Wong et al. [22] (2007)	1	1	2	2	2	2	10

1) Yes = 1, no = 0

2) Diagnostic system reported = 1. Own system/symptoms described/no system/not specified = 0

3) Community survey/multiple institutions = 2. Inpatient/inpatients and outpatients/case registers = 1. Not specified = 0

4) Administered interview = 3. Systematic case note review = 2. Chart diagnosis/case records = 1. Not specified = 0

5) Broadly representative (national or multi-site survey) = 2. Small area/not representative (single community, single university) = 1. Convenience sampling/other (primary care sample/treatment group) = 0

6) Point prevalence (e.g., 1-month prevalence = 2; 12-month prevalence = 1; lifetime prevalence = 0)